Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Review Article

EJMCM. 2018; 5(1): 20-29


Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient

Geeta Yadav, Piyush Kumar, Yugal Kumar, Pradeep Kumar Singh.

Abstract
Undeterred efforts are reported and still continue in future to achieve the goals of virologic suppression in HIV-infected individuals. Dolutegravir is the result of all the efforts made in this direction. It is a recent integrase inhibitor drug approved by the US FDA (Food and Drug Administration) for use in the treatment-naïve and treatment-experienced HIV-infected patients. This article has reviewed all the aspects of the drug, including the structural and functional analyses, in vitro activity, pharmacokinetics, drug-drug interactions, MOA, metabolism, excretion, dosing/adverse effects and resistance profile. Dolutegravir is a potent and well tolerated antiretroviral agent that can play an important role in the treating patients harboring resistance to other antiretrovirals. Some new combinations of drug with other antiretrovirals are also in the pipeline that can increase the immunologic response of the HIV
patients.

Key words: Dolutegravir; Antiretroviral; Integrase inhibitor; Human Immunodeficiency Virus (HIV)



Similar Articles

Promoter CAG is more efficient than hepatocyte‑targeting TBG for transgene expression via rAAV8 in liver tissues.
Kang J, Hang L, Zheng W, Luo J, Zhang X, Song Y, Liu A
Molecular medicine reports. 2022; 25(1):

Biovalue in Human Brain Banking: Applications and Challenges for Research in Neurodegenerative Diseases.
Vedam-Mai V
Methods in molecular biology (Clifton, N.J.). 2022; 2389(): 209-220

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44

Differentiating Human Pluripotent Stem Cells to Vascular Endothelial Cells for Regenerative Medicine, Tissue Engineering, and Disease Modeling.
Bertucci T, Kakarla S, Kim D, Dai G
Methods in molecular biology (Clifton, N.J.). 2022; 2375(): 1-12

New insights into Epstein‑Barr virus‑associated tumors: Exosomes (Review).
Chen W, Xie Y, Wang T, Wang L
Oncology reports. 2022; 47(1):


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites